The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug-reactive T cells in resolved hypersensitivity cases and drug-naïve healthy donors.


Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
11 2023
Historique:
revised: 07 06 2023
received: 20 04 2023
accepted: 10 06 2023
medline: 13 11 2023
pubmed: 15 7 2023
entrez: 15 7 2023
Statut: ppublish

Résumé

Allopurinol (ALP) is a successful drug used in the treatment of gout. However, this drug has been implicated in hypersensitivity reactions that can cause severe to life-threatening reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Individuals who carry the human leukocyte antigen (HLA)-B*58:01 allotype are at higher risk of experiencing a hypersensitivity reaction (odds ratios ranging from 5.62 to 580.3 for mild to severe reactions, respectively). In addition to the parent drug, the metabolite oxypurinol (OXP) is implicated in triggering T cell-mediated immunopathology via a labile interaction with HLA-B*58:01. To date, there has been limited information regarding the T-cell receptor (TCR) repertoire usage of reactive T cells in patients with ALP-induced SJS or TEN and, in particular, there are no reports examining paired αβTCRs. Here, using in vitro drug-treated PBMCs isolated from both resolved ALP-induced SJS/TEN cases and drug-naïve healthy donors, we show that OXP is the driver of CD8

Identifiants

pubmed: 37452515
doi: 10.1111/all.15814
doi:

Substances chimiques

Allopurinol 63CZ7GJN5I
Oxypurinol G97OZE5068
HLA-B Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2980-2993

Subventions

Organisme : Monash University
Organisme : National Health and Medical Research Council of Australia

Informations de copyright

© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Références

Chem Res Toxicol. 2013 May 20;26(5):759-66
pubmed: 23541086
Pharmacogenet Genomics. 2011 May;21(5):303-7
pubmed: 21301380
Clin Immunol Immunopathol. 1994 Feb;70(2):145-51
pubmed: 8299230
J Invest Dermatol. 2013 May;133(5):1197-204
pubmed: 23389396
Nat Med. 2008 Dec;14(12):1343-50
pubmed: 19029983
Pharmacogenomics. 2008 Nov;9(11):1617-22
pubmed: 19018717
Tissue Antigens. 2011 Jul;78(1):11-20
pubmed: 21501118
Clin Pharmacokinet. 2007;46(8):623-44
pubmed: 17655371
J Allergy Clin Immunol. 2004 Nov;114(5):1209-15
pubmed: 15536433
Nat Rev Rheumatol. 2016 Apr;12(4):235-42
pubmed: 26416594
J Immunol. 2014 Apr 1;192(7):2984-93
pubmed: 24591375
J Immunol. 2014 Jun 1;192(11):5039-49
pubmed: 24778446
Am J Transplant. 2008 Jan;8(1):121-32
pubmed: 18093278
Nature. 2012 Jun 28;486(7404):554-8
pubmed: 22722860
J Allergy Clin Immunol. 2011 Dec;128(6):1266-1276.e11
pubmed: 21924464
Nat Biotechnol. 2004 May;22(5):589-94
pubmed: 15064769
Pharmacogenomics. 2010 Jul;11(7):973-87
pubmed: 20602616
Br J Dermatol. 2013 Sep;169(3):660-5
pubmed: 23600531
Clin Chim Acta. 1990 Mar 15;187(3):221-34
pubmed: 2323062
Front Immunol. 2021 Apr 12;12:653710
pubmed: 33912179
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4134-9
pubmed: 15743917
Drug Saf. 2013 Oct;36(10):953-80
pubmed: 23873481
AIDS. 2012 Jul 17;26(11):F21-9
pubmed: 22617051
Pharmacogenet Genomics. 2009 Sep;19(9):704-9
pubmed: 19696695
Sci Transl Med. 2012 Apr 4;4(128):128ra42
pubmed: 22491952
J Am Acad Dermatol. 2008 Jan;58(1):25-32
pubmed: 17919772
Comput Struct Biotechnol J. 2023 Feb 03;21:1272-1282
pubmed: 36814721
J Allergy Clin Immunol. 2012 Jun;129(6):1562-9.e5
pubmed: 22322005
J Clin Invest. 1998 Oct 15;102(8):1591-8
pubmed: 9788973
J Allergy Clin Immunol. 2015 Apr;135(4):1063-1065.e5
pubmed: 25458913
N Engl J Med. 1972 Mar 9;286(10):505-7
pubmed: 4258181
Cell. 1978 May;14(1):9-20
pubmed: 667938
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8
pubmed: 18503082
Clin Exp Allergy. 2013 Nov;43(11):1246-55
pubmed: 24152157
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9959-64
pubmed: 22645359
J Invest Dermatol. 2016 Jul;136(7):1373-1381
pubmed: 26996548
Ann Rheum Dis. 1981 Jun;40(3):245-9
pubmed: 7247470
Ann Rheum Dis. 2015 Dec;74(12):2157-64
pubmed: 25115449
Pharmacogenet Genomics. 2008 Feb;18(2):99-107
pubmed: 18192896
J Invest Dermatol. 2015 Sep;135(9):2237-2248
pubmed: 25946710
Allergy. 2023 Nov;78(11):2980-2993
pubmed: 37452515
World Allergy Organ J. 2008 Jun;1(6):96-102
pubmed: 23282405
J Allergy Clin Immunol. 2019 Nov;144(5):1413-1416.e7
pubmed: 31574267
Nat Commun. 2019 Aug 8;10(1):3569
pubmed: 31395875
Mol Pharmacol. 2003 Mar;63(3):732-41
pubmed: 12606784
J Immunol. 1992 Mar 15;148(6):1941-8
pubmed: 1541831
J Am Acad Dermatol. 2013 May;68(5):709.e1-9; quiz 718-20
pubmed: 23602183
Arthritis Rheum. 1988 Mar;31(3):436-40
pubmed: 3358806
Exp Clin Immunogenet. 2000;17(4):205-15
pubmed: 11096259
Clin Exp Allergy. 2000 Jun;30(6):847-55
pubmed: 10848903
Transplantation. 2010 Dec 27;90(12):1439-49
pubmed: 21042237
Curr Opin Immunol. 2016 Oct;42:31-40
pubmed: 27261882

Auteurs

Nicole A Mifsud (NA)

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Patricia T Illing (PT)

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Rebecca Ho (R)

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Johanna E Tuomisto (JE)

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Heidi Fettke (H)

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Kerry A Mullan (KA)

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

James McCluskey (J)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.

Jamie Rossjohn (J)

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Julian Vivian (J)

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Rangsima Reantragoon (R)

Immunology Division, Department of Microbiology, Department of Microbiology, Chulalongkorn University, Bangkok, Thailand.
Center of Excellence in Immunology and Immune-mediated Disease, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Anthony W Purcell (AW)

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH